Thiazolidinediones Not Linked to Colon Polyps in Type 2 DiabeticsDECEMBER 30, 2008
James D. Lewis, MD, MSCE, Associate Professor of Medicine and Epidemiology, and Senior Scholar, Center for Clinical Epidemiology and Biostatistics, appears in Modern Medicine and HealthDay for his resent research published in the December issue of Gastroenterology. Lewis and colleagues report that in patients with type 2 diabetes, thiazolidinediones – such as the drug Avandia – do not appear to increase the risk of colonic neoplasia, or polyps. According to Dr. Lewis, et al, "Because it will take decades to sufficiently follow large cohorts to address the risk of colon cancer following thiazolidinedione exposure, we studied development of adenomatous polyps. We did not obtain evidence to indicate that exposure to thiazolidinediones increases the risk of colonic neoplasia."